Safety of macitentan in portopulmonary hypertension (PoPH): Real-world experience by liver transplant candidacy in the OPUS registry
H. DuBrock (Rochester, United States of America), R. Channick (Los Angeles, United States of America), N. Kim (La Jolla, United States of America), V. Mclaughlin (Ann Arbor, United States of America), P. Agron (South San Francisco, United States of America), S. Leroy (Allschwil, Switzerland), G. Wetherill (Allschwil, Switzerland), K. Chin (Dallas, United States of America)
Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. DuBrock (Rochester, United States of America), R. Channick (Los Angeles, United States of America), N. Kim (La Jolla, United States of America), V. Mclaughlin (Ann Arbor, United States of America), P. Agron (South San Francisco, United States of America), S. Leroy (Allschwil, Switzerland), G. Wetherill (Allschwil, Switzerland), K. Chin (Dallas, United States of America). Safety of macitentan in portopulmonary hypertension (PoPH): Real-world experience by liver transplant candidacy in the OPUS registry. 1464
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: